These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 34183491)

  • 1. Targeted radionuclide therapy: an emerging field in solid tumours.
    Artigas C; Mileva M; Flamen P; Karfis I
    Curr Opin Oncol; 2021 Sep; 33(5):493-499. PubMed ID: 34183491
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Radiopharmaceuticals for the Diagnosis and Therapy of Neuroendocrine Differentiated Prostate Cancer.
    Giovacchini G; Giovannini E; Riondato M; Ciarmiello A
    Curr Radiopharm; 2017; 10(1):6-15. PubMed ID: 28034291
    [TBL] [Abstract][Full Text] [Related]  

  • 3. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor imaging and therapy using radiolabeled somatostatin analogues.
    de Jong M; Breeman WA; Kwekkeboom DJ; Valkema R; Krenning EP
    Acc Chem Res; 2009 Jul; 42(7):873-80. PubMed ID: 19445476
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [
    Hofman MS; Violet J; Hicks RJ; Ferdinandus J; Thang SP; Akhurst T; Iravani A; Kong G; Ravi Kumar A; Murphy DG; Eu P; Jackson P; Scalzo M; Williams SG; Sandhu S
    Lancet Oncol; 2018 Jun; 19(6):825-833. PubMed ID: 29752180
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preclinical Development in Radiopharmaceutical Therapy for Prostate Cancer.
    Alati S; Singh R; Pomper MG; Rowe SP; Banerjee SR
    Semin Nucl Med; 2023 Sep; 53(5):663-686. PubMed ID: 37468417
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recent advances in theranostics and challenges for the future.
    Turner JH
    Br J Radiol; 2018 Nov; 91(1091):20170893. PubMed ID: 29565650
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ¹⁷⁷Lu-Labeled Agents for Neuroendocrine Tumor Therapy and Bone Pain Palliation in Uruguay.
    Balter H; Victoria T; Mariella T; Javier G; Rodolfo F; Andrea P; Graciela R; Juan H; Eugenia de M; Patricia O
    Curr Radiopharm; 2016; 9(1):85-93. PubMed ID: 25771367
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Radiolabelled somatostatin analogue(s) for peptide receptor scintigraphy and radionuclide therapy.
    Krenning EP; de Jong M; Kooij PP; Breeman WA; Bakker WH; de Herder WW; van Eijck CH; Kwekkeboom DJ; Jamar F; Pauwels S; Valkema R
    Ann Oncol; 1999; 10 Suppl 2():S23-9. PubMed ID: 10399029
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Theranostics of Metastatic Prostate Cancer Applying
    Mirzaei S; Mohammed F; Zandieh S
    Curr Radiopharm; 2021; 14(4):354-358. PubMed ID: 32900357
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prostate-specific membrane antigen for prostate cancer theranostics: from imaging to targeted therapy.
    Arsenault F; Beauregard JM; Pouliot F
    Curr Opin Support Palliat Care; 2018 Sep; 12(3):359-365. PubMed ID: 29939893
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of the PSMA-Binding Ligand
    Stenberg VY; Larsen RH; Ma LW; Peng Q; Juzenas P; Bruland ØS; Juzeniene A
    Int J Mol Sci; 2021 May; 22(9):. PubMed ID: 34062920
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ENZA-p trial protocol: a randomized phase II trial using prostate-specific membrane antigen as a therapeutic target and prognostic indicator in men with metastatic castration-resistant prostate cancer treated with enzalutamide (ANZUP 1901).
    Emmett L; Subramaniam S; Joshua AM; Crumbaker M; Martin A; Zhang AY; Rana N; Langford A; Mitchell J; Yip S; Francis R; Hofman MS; Sandhu S; Azad A; Gedye C; McJannett M; Stockler MR; Davis ID;
    BJU Int; 2021 Nov; 128(5):642-651. PubMed ID: 34028967
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prostate-Specific Membrane Antigen (PSMA)-Targeted Radionuclide Therapies for Prostate Cancer.
    Sun M; Niaz MJ; Niaz MO; Tagawa ST
    Curr Oncol Rep; 2021 Mar; 23(5):59. PubMed ID: 33778927
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeted Radionuclide Therapy of Prostate Cancer-From Basic Research to Clinical Perspectives.
    Czerwińska M; Bilewicz A; Kruszewski M; Wegierek-Ciuk A; Lankoff A
    Molecules; 2020 Apr; 25(7):. PubMed ID: 32290196
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Examining Absorbed Doses of Indigenously Developed
    Kamaldeep ; Wanage G; Sahu SK; Maletha P; Adnan A; Suman S; Basu S; Das T; Banerjee S
    Cancer Biother Radiopharm; 2021 Apr; 36(3):292-304. PubMed ID: 32379495
    [No Abstract]   [Full Text] [Related]  

  • 17. Peptide Receptor Radionuclide Therapy for Advanced Gastroenteropancreatic Neuroendocrine Tumors - from oncology perspective.
    Kolasińska-Ćwikła A; Łowczak A; Maciejkiewicz KM; Ćwikła JB
    Nucl Med Rev Cent East Eur; 2018; 21(2):. PubMed ID: 29741203
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prostate-Specific Membrane Antigen Radioligand Therapy Using
    Schuchardt C; Zhang J; Kulkarni HR; Chen X; Müller D; Baum RP
    J Nucl Med; 2022 Aug; 63(8):1199-1207. PubMed ID: 34887335
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Theranostic approaches in nuclear medicine: current status and future prospects.
    Filippi L; Chiaravalloti A; Schillaci O; Cianni R; Bagni O
    Expert Rev Med Devices; 2020 Apr; 17(4):331-343. PubMed ID: 32157920
    [No Abstract]   [Full Text] [Related]  

  • 20. Preclinical Development of Novel PSMA-Targeting Radioligands: Modulation of Albumin-Binding Properties To Improve Prostate Cancer Therapy.
    Umbricht CA; Benešová M; Schibli R; Müller C
    Mol Pharm; 2018 Jun; 15(6):2297-2306. PubMed ID: 29684274
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.